Formulation, Development and Evaluation of Topiramate Loaded Niosomes for the Treatment of Epilepsy

Topiramate (TPM) is an anti-epileptic drug used in the treatment of epilepsy and seizures. The study was designed with three aims. First, to enhance the solubility and bioavailability of BCS class III drug TPM; second, to ease administration of the formulation to the epileptic patient, during an attack, and third, to decrease the dose of drug for enduring treatment. Formulation of TPM niosomes was optimized by changing the concentration of Tween, Labrafil and cholesterol using response surface design. Further the TPM niosomes were prepared by using ether injection method. The formulation was then evaluated for vesicle size, entrapment efficiency and in-vitro drug release study. FTIR and DSC studies were performed for pure drug and optimized batch. The vesicle size of the optimized batch was found to be 0. 35 nm. The %entrapment efficiency and %drug release of optimized batch was found to be 94.64% and 92.027% respectively. From the present study it can be concluded that the developed niosomes of TPM has shown great potential in treatment of epilepsy.